The issue of concern therewith is Linda cannot partially release information/data regarding DCVax-L 3 trial, particularly ever since the Summer 2015 when the trial was partially halted from screening new patients.
The event was negative despite a few longs suggest otherwise, with the reason probably related to "unexpected" significant pseudo-progression, which in nature was a positive thing to have indicating higher than expected immune-reaction to DCvax vaccine, but it also suggested the flaw of the initial design as Dr. Liau had explained fully shortly afterwards.
Long story short, now the issue of the initial flawed design has been corrected by extending the trial to unprecedented length enabling adapted SAP, endpoint reordering so that the trial outcomes can be appropriately measures.
So the time for a full release of information/data needs to wait until after the now-7-months locked data to be "carefully and thoroughly" analyzed by statisticians, PI, the company, Steering Committee, the Advisory Board, and and a panel of independent experts.
The good thing is for all what we have known, the trial outcomes will be significant, and the vaccine will be approved in all four countries, and beyond, which warrants an "all in" investment as of today.
News 
Market Data 
Discover 
